Top Qs
Timeline
Chat
Perspective
Danuglipron
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Danuglipron is a small-molecule GLP-1 agonist, formerly under development by Pfizer[1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.[2][3] However, in April 2025, Pfizer announced it would abandon further development of Danuglipron due to unpredictable liver toxicity.[4]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads